FDA Pilot Program Eases Rules for Nicotine Pouch Makers 
Rio Tinto Raises 2025 Copper Output Outlook as Oyu Tolgoi Expansion Accelerates 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition 
Intel Boosts Malaysia Operations with Additional RM860 Million Investment 
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation 
Lab-grown meat: you may find it icky, but it could drive forward medical research 
Pfizer Secures $10 Billion Deal for Obesity Drug Developer Metsera, Outbids Novo Nordisk 
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission 
YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban 
NASA Resumes Cygnus XL Cargo Docking with Space Station After Software Fix 
SpaceX Starship Explodes in Texas During Test, Citing Nitrogen Tank Failure 
Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts 
Microchip Technology Boosts Q3 Outlook on Strong Bookings Momentum 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
Neuralink Expands Brain Implant Trials with 12 Global Patients 
Eli Lilly has announced that the U.S. Food and Drug Administration (FDA) has approved its new therapy, Inluriyo, for the treatment of advanced or metastatic breast cancer in adult patients who have already undergone prior therapy. This milestone approval marks a significant advancement in addressing a challenging form of cancer that often resists standard treatments.
Metastatic breast cancer, also known as Stage IV breast cancer, occurs when cancer spreads beyond the breast and nearby lymph nodes to other organs such as the bones, liver, lungs, or brain. Certain breast cancers develop ESR1 mutations, which cause estrogen receptors to become overly active. While these receptors normally regulate cell growth, their mutation can accelerate cancer progression. Inluriyo directly targets these receptors by binding to and breaking them down, effectively blocking their activity to help slow disease progression.
The FDA’s decision was based on data from a late-stage clinical trial showing that patients treated with Inluriyo had a 38% lower risk of disease progression or death compared to those receiving standard therapies. On average, patients taking Inluriyo went 5.5 months without cancer worsening, versus 3.8 months with other treatments.
Inluriyo is an oral therapy recommended at a daily dose of 400 mg—taken as two 200 mg tablets on an empty stomach. The drug will be available in the U.S. within weeks at a list price of $22,500 per 28-day cycle. Eli Lilly highlighted that the medication carries an embryo-fetal toxicity warning, underscoring the risks of exposure during pregnancy.
The company is also investigating Inluriyo in combination with abemaciclib, another Lilly therapy, for advanced breast cancer, as well as in early-stage disease as adjuvant treatment.
With its approval, Inluriyo offers patients with metastatic breast cancer and ESR1 mutations a new, targeted treatment option that could improve outcomes and provide hope in one of the toughest stages of breast cancer.
